Group 1 - The company held its 17th meeting of the second board on October 12, 2025, with all 10 directors present, and the meeting was conducted in accordance with relevant laws and regulations [2][5][6] - The board approved the signing of a licensing agreement for the CoolMPS sequencing technology with Swiss Rockets AG, granting exclusive rights outside the Asia-Pacific and Greater China regions [3][9][11] - The company will receive a minimum of $120 million in licensing fees from the agreement, including a non-refundable upfront payment of $20 million and milestone payments [11][41] Group 2 - The company plans to acquire shared patents related to the CoolMPS sequencing technology and stLFR library construction technology from its affiliate, BGI Research Institute, to streamline intellectual property management [10][42] - The board's decision on the licensing agreement and patent acquisition will be submitted for approval at the upcoming shareholder meeting on October 28, 2025 [8][12][46] - The licensing agreement is expected to positively impact the company's future performance and enhance its global commercialization and profitability [12][41] Group 3 - Swiss Rockets AG, the counterparty in the licensing agreement, is a Swiss-based innovative enterprise focused on biotechnology, with a strong emphasis on oncology and infectious diseases [18][19] - The company has established a solid financial standing, with total assets of approximately 5.77 million Swiss francs and a net profit of -14.38 million Swiss francs for 2024 [19] - The agreement includes provisions for revenue sharing based on net sales of licensed products, with a tiered royalty structure [11][31] Group 4 - The company aims to leverage the licensing agreement to realize the value of its technology without additional R&D investment, thereby improving profitability and cash flow [41] - The acquisition of shared patents is intended to eliminate ownership barriers and allow the company to act as the sole rights holder for future licensing [42] - The board's review process included assessments from the audit committee, independent directors, and the supervisory board, all of which supported the transaction [43][45][47]